Dr. Kwa is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
160 East 34th Street
New York, NY 10016Phone+1 212-731-6364
Education & Training
- NYU Grossman School of MedicineFellowship, Hematology and Medical Oncology, 2013 - 2016
- NYU Grossman School of MedicineResidency, Internal Medicine, 2009 - 2012
- Georgetown University School of MedicineClass of 2009
Certifications & Licensure
- NY State Medical License 2011 - 2026
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Trial of Nivolumab With Chemotherapy as Neoadjuvant Treatment in Inflammatory Breast Cancer (IBC) Start of enrollment: 2019 May 02
- Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast Start of enrollment: 2017 Dec 20
Roles: Contact
Publications & Presentations
PubMed
- 306 citationsThe Intestinal Microbiome and Estrogen Receptor-Positive Female Breast Cancer.Maryann Kwa, Claudia S. Plottel, Martin J. Blaser, Sylvia Adams
Journal of the National Cancer Institute. 2016-08-01 - 135 citationsCheckpoint inhibitors in triple‐negative breast cancer (TNBC): Where to go from hereMaryann J. Kwa, Sylvia Adams
Cancer. 2018-05-15 - 15 citationsSerial immunological parameters in a phase II trial of exemestane and low-dose oral cyclophosphamide in advanced hormone receptor-positive breast cancer.Maryann Kwa, Xiaochun Li, Yelena Novik, Ruth Oratz, Komal Jhaveri
Breast Cancer Research and Treatment. 2018-02-01
Press Mentions
- What It's like Battling Breast Cancer and the Coronavirus—at the Same TimeOctober 6th, 2020
- To Host State of the Science Summit™ on Breast CancerJune 14th, 2018
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: